Central Precocious Puberty (CPP)

DBCOND0040295Endocrine System DiseasesUrogenital Diseases

Central Precocious Puberty (CPP) is the indication for 3 drugs in DrugBank. It is covered by 4 curated, structured indications.

Also known as
Central Precocious Puberty · Precocious Puberty, Central · Puberty, Central Precocious · Puberty; Precocious, Central
Classified under
Indicated drugs

Resolves to

Vocabularies
MeSHM0563087ICD-10E22.8SNOMED CT123527003MedDRA10000359UMLSC0034013

What you can answer from here — as of October 22, 2026

3Indicated drugsWith each drug's targets and mechanism
Listed above
4Structured indicationsPopulation, line of therapy, route and combination as fields, not prose
Sign in
20Clinical trialsPhase, status and sponsor resolved per trial
Sign in
3Drugs reporting it as an adverse effectWith incidence where the label states it
Sign in

Which approved drugs for Central Precocious Puberty (CPP) share a target, and which companies have late-stage candidates against it?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In